¼¼°èÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå : Á¦Ç° À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº° - ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2024-2035³â)
Peripheral Artery Disease Market By Product Type (Devices, Drugs), By End User (Hospitals, Specialty Clinics): Global Opportunity Analysis and Industry Forecast, 2024-2035
»óǰÄÚµå : 1513334
¸®¼­Ä¡»ç : Allied Market Research
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 280 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,730 £Ü 8,290,000
PDF (Business License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 2¸í ÀÌ»óÀÌ ÀÌ¿ëÇÒ °æ¿ì, Ãß°¡ ¿ä±ÝÀ» ÁöºÒÇÏ¿© ¶óÀ̼±½º ¾÷±×·¹À̵å·Î ÃÖ´ë 5¸í±îÁö ÀÌ¿ë °¡´ÉÇÕ´Ï´Ù.
US $ 9,600 £Ü 13,890,000
PDF (Enterprise User License) & Excel (Data Pack) & Free Update help
PDF º¸°í¼­ ¹× Excel µ¥ÀÌÅ͸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. º¸°í¼­ ¾÷µ¥ÀÌÆ® ¼­ºñ½º°¡ ¹«·á·Î Á¦°øµË´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀåÀº 2023³â 45¾ï ´Þ·¯·Î Æò°¡µÇ¸ç 2024³âºÎÅÍ 2035³â±îÁö ¿¬Æò±Õ 7.7% ¼ºÀåÇÏ¿© 2035³â¿¡´Â 108¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¸»Ãʵ¿¸ÆÁúȯÀº »çÁö(º¸Åë ´Ù¸®)¿¡ Ç÷¾×À» °ø±ÞÇÏ´Â µ¿¸ÆÀÌ Á¼¾ÆÁö°Å³ª ¸·È÷´Â °ÍÀ» Ư¡À¸·Î ÇÏ´Â ÁúȯÀÔ´Ï´Ù. ÀÌ´Â µ¿¸Æ¿¡ Áö¹æ Ä§Âø¹°(ÇöóÅ©)ÀÌ ½×¿© µ¿¸Æ°æÈ­ÁõÀ¸·Î ¾Ë·ÁÁø µ¿¸Æ°æÈ­ÁõÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ±× °á°ú ´Ù¸®·Î °¡´Â Ç÷·ù°¡ Á¦ÇÑµÇ¾î ´Ù¸® ÅëÁõ, °æ·Ã, ¹«°¨°¢, ¹«·Â°¨, ƯÈ÷ ¿îµ¿ ½Ã ´Ù¸® ÅëÁõ°ú °°Àº Áõ»óÀÌ ³ªÅ¸³³´Ï´Ù. ¸»Ãʵ¿¸ÆÁúȯÀÇ Ä¡·á´Â Áõ»óÀ» °ü¸®Çϰí ÇÕº´ÁõÀ» ¿¹¹æÇϸç Ç÷·ù¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¸·Èù µ¿¸ÆÀ» ¿­¾î Ç÷·ù¸¦ ȸº¹½Ã۱â À§ÇØ ½Ã¼úÀ̳ª ¼ö¼úÀÌ ÇÊ¿äÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â Ç÷°ü ¼ºÇü¼ú(dz¼±À¸·Î µ¿¸ÆÀ» ³ÐÇôÁÖ´Â ½Ã¼ú)°ú ½ºÅÙÆ® »ðÀÔ¼ú(µ¿¸ÆÀ» ¿­¾îÁÖ´Â ½Ã¼ú)ÀÌ Æ÷ÇԵ˴ϴÙ.

Peripheral Artery Disease Market-IMG1

¸»Ãʵ¿¸ÆÁúȯ ½ÃÀåÀÇ ¼ºÀå¼¼´Â ³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í ÃÖ¼Òħ½À ¼ö¼ú ±â¼úÀÇ ¹ßÀü¿¡ ±âÀÎÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ 2022³â º¸°í¼­¿¡ µû¸£¸é, ³ëÀÎ Àα¸(60¼¼ ÀÌ»ó)´Â Àü ¼¼°è Àα¸ÀÇ ¾à 22%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ³ªÀ̰¡ µé¾î°¨¿¡ µû¶ó, ƯÈ÷ ´ç´¢º´, °íÇ÷¾Ð, Èí¿¬·Â µî ´Ù¸¥ ½ÉÇ÷°ü À§Çè ¿äÀÎÀ» °¡Áø »ç¶÷µé »çÀÌ¿¡¼­ ¸»ÃÊ µ¿¸Æ ÁúȯÀÌ ¹ß»ýÇÒ À§ÇèÀÌ Áõ°¡ÇÕ´Ï´Ù. ¸¹Àº ±¹°¡¿¡¼­ Àα¸ Åë°è°¡ °í·ÉÃþÀ¸·Î À̵¿ÇÔ¿¡ µû¶ó ¸»ÃÊ µ¿¸Æ ÁúȯÀÇ ¹ß»ý·ü°ú À¯º´·üÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, National Library of MedicineÀÇ 2023³â º¸°í¼­¿¡ µû¸£¸é 70¼¼ À̻󿡼­ ¸»ÃÊ µ¿¸Æ ÁúȯÀÇ ¹ß»ý·üÀÌ 20%±îÁö Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º¸°íµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ ³ëÀÎ Àα¸´Â ¸»Ãʵ¿¸ÆÁúȯ ¹ßº´·üÀÌ ³ô±â ¶§¹®¿¡ ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½ÀÀû ½Ã¼úÀÇ ±â¼ú ¹ßÀüÀº ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, Áø´Ü ¹× Ä¡·áÀÇ »óȲÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. Ç÷°ü¼ºÇü¼ú, ½ºÅÙÆ®»ðÀÔ¼ú, Á׻󵿸ÆÀýÁ¦¼ú°ú °°Àº ÃÖ¼Òħ½ÀÀû ±â¼úÀº ±âÁ¸ÀÇ °³º¹¼ö¼ú¿¡ ´ëÇÑ º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ¸»Ãʵ¿¸ÆÁúȯÀÇ °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼úÀº ±âÁ¸ ¼ö¼úÀû Á¢±Ù ¹æ½Ä¿¡ ºñÇØ Àý°³Ã¢ÀÌ ÀÛ°í, ÁÖº¯ Á¶Á÷¿¡ ´ëÇÑ ¿Ü»óÀÌ ÀûÀ¸¸ç, ȸº¹ ½Ã°£ÀÌ Âª°í, ÇÕº´Áõ À§ÇèÀÌ ³·½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼±µµÀû ÀÎ ÀÇ·á±â±â Á¦Á¶¾÷ü ÀÎ Medtronic Plc´Â ¿ÏÀüÇÑ SE Ç÷°ü ½ºÅÙÆ® ½Ã½ºÅÛÀ» Á¦°øÇÕ´Ï´Ù. ¿ÏÀüÇÑ SE Ç÷°ü ½ºÅÙÆ® ½Ã½ºÅÛÀº Ç¥À缺 ´ëÅ𠵿¸Æ°ú ±ÙÀ§ ½½¿Í µ¿¸ÆÀÇ ¸»ÃÊ µ¿¸Æ ÁúȯÀ» Ä¡·áÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â ¸·Èù µ¿¸ÆÀ» ¿­°í Ç÷°ü ¼ºÇü¼ú ÈÄ µ¿¸ÆÀ» ÁöÁöÇÏ¿© Ç÷·ù¸¦ ȸº¹Çϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀåÀº Á¦Ç° À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°·Î ¼¼ºÐÈ­µË´Ï´Ù. Á¦Ç° À¯Çüº°·Î ½ÃÀåÀº ¾à¹°°ú ÀåÄ¡·Î ±¸ºÐµË´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚº°·Î ½ÃÀåÀº º´¿ø, Àü¹® Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ·Î ³ª´¹´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(ÀϺ», Áß±¹, È£ÁÖ, Àεµ, Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), ³²¹Ì(ºê¶óÁú, »ç¿ìµð¾Æ¶óºñ¾Æ, ¾ÆÇÁ¸®Ä«, ±âŸ ³²¹Ì Áö¿ª)·Î ºÐ¼®µË´Ï´Ù. ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, Cardinal Health, Abbott µîÀÌ ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀåÀÇ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °³¼±Çϱâ À§ÇÑ ÁÖ¿ä °³¹ß Àü·«À¸·Î Á¦Ç° ½ÂÀÎÀ» äÅÃÇϰí ÀÖÀ¸¸ç, ÀÌÇØ°ü°èÀÚ¸¦ À§ÇÑ ÁÖ¿ä ÀÌÁ¡Àº ´ÙÀ½°ú °°½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå : Á¦Ç° À¯Çüº°

Á¦5Àå ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦6Àå ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå : Áö¿ªº°

Á¦7Àå °æÀï »óȲ

Á¦8Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global peripheral artery disease market was valued at $4.5 billion in 2023, and is estimated to reach $10.8 billion by 2035, growing at a CAGR of 7.7% from 2024 to 2035. Peripheral artery disease is a condition characterized by the narrowing or blockage of arteries that supply blood to the limbs, typically the legs. This occurs due to the buildup of fatty deposits (plaques) in the arteries, a process known as atherosclerosis. As a result, blood flow to the legs is restricted, leading to symptoms such as leg pain, cramping, numbness, and weakness, particularly during physical activity. Treatment for peripheral artery disease aims to manage symptoms, prevent complications, and improve blood flow. Procedures or surgeries may be required to open blocked arteries and restore blood flow. These can include angioplasty (where a balloon is used to widen the artery) or stent placement (to keep the artery open).
Peripheral Artery Disease Market - IMG1
The peripheral artery disease market growth is attributed to rise in geriatric population, and technological advancements in minimally invasive surgical technology. According to 2022 report by World Health Organization, it was estimated that, the geriatric population (aged 60 and above) is expected to contribute about 22% of global population. As people age, the risk of developing peripheral artery disease rises, especially among those with other cardiovascular risk factors such as diabetes, hypertension, and smoking history. With populations in many countries experiencing a demographic shift towards older age brackets, the incidence and prevalence of peripheral artery disease are expected to escalate. According to the 2023 report by the National Library of Medicine, it was reported that incidence of peripheral artery disease increases to as high as 20% in people over the age of 70. Thus, as the geriatric population has a higher incidence rate of peripheral artery disease, the rise in geriatric population is expected to positively impact the growth of peripheral artery disease market.In addition, technological advancements in minimally invasive procedures have emerged as a major driver for the peripheral artery disease market, transforming the landscape of diagnosis and treatment. Minimally invasive techniques, such as angioplasty, stenting, and atherectomy, have revolutionized the management of peripheral artery disease by offering safer and more effective alternatives to traditional open surgeries. These procedures involve smaller incisions, reduced trauma to surrounding tissues, shorter recovery times, and lower risk of complications compared to conventional surgical approaches. For instance, Medtronic Plc, a leading medical devices company, provides a complete SE vascular stent system. The complete SE vascular stent system is designed to treat peripheral arterial disease in the superficial femoral arteries and proximal popliteal arteries. The stent is designed to open clogged arteries and restore blood flow by providing support to the artery after angioplasty. Thus, the advantages of minimally invasive procedures such as shorter hospital stays and reduced physical trauma (caused in traditional open surgery) are expected to drive the growth of the market.The peripheral artery disease market is segmented by product type, end user, and region. By product type the market is bifurcated into drugs and devices. By end user, the market is divided into hospitals, specialized clinics and ambulatory surgeries centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the peripheral artery disease market are Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, Cardinal Health, Abbott. Key players have adopted product approval as a key developmental strategy to improve the product portfolio of the peripheral artery disease marketKey Benefits For Stakeholders

Additional benefits you will get with this purchase are:

Key Market Segments

By Product Type

By End User

By Region

Key Market Players:

Medical Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE

CHAPTER 5: PERIPHERAL ARTERY DISEASE MARKET, BY END USER

CHAPTER 6: PERIPHERAL ARTERY DISEASE MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â